Compare Novo Nordisk A/S (NVO) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Redwire Corporation — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Redwire Corporation trades at $9.58 (market cap $2.44B). The key difference: Novo Nordisk A/S is far larger — about 67.8× Redwire Corporation's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Redwire Corporation for 18 Days on average.
| NVO | RDW | |
|---|---|---|
Market Cap | $165.31B | $2.44B |
Volume | 11,432,838 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $63.98 | $25.90 |
52-Week Low | $35.29 | $5.06 |
Typical Hold Time | 116 Days | 18 Days |
Enterprise Value | $179.56B | $1.97B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
RDW trades at $9.76, down 4.69% on the day, reflecting a bearish technical trend. The company reported a net loss of $226.55M in 2025, with a negative net margin of -57.26%, though revenue grew to $335.38M. Recent news highlights strategic partnerships, including a $981M Space Force contract and collaborations with Honda and Sophia Space on robotics and orbital data centers, signaling growth potential in the space infrastructure sector.
The outlook is mixed: strong analyst consensus (80% buy ratings) and a $14.88 price target suggest upside, but persistent losses, negative cash flow from operations, and dependence on SpaceX's success pose significant risks. Investors face high volatility amid speculative growth prospects in the evolving space economy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
